|
SNX24 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.0507999742847E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
7.018052805563E-12 |
| Stage1-vs-Stage2 |
4.541000E-01 |
| Stage1-vs-Stage3 |
4.826800E-01 |
| Stage1-vs-Stage4 |
6.239800E-01 |
| Stage2-vs-Stage3 |
2.720200E-01 |
| Stage2-vs-Stage4 |
7.651600E-01 |
| Stage3-vs-Stage4 |
3.462400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.86929999987673E-07 |
| Normal-vs-Asian |
1.63624669369256E-12 |
| Caucasian-vs-AfricanAmerican |
4.306200E-01 |
| Caucasian-vs-Asian |
1.683940E-03 |
| AfricanAmerican-vs-Asian |
1.934600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
6.452400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.678820E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.663000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.602600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.357880E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.557200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.099000E-03 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.479230E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.012600E-01 |
| Classical-VS-Follicular |
8.270200E-01 |
| Classical-VS-Other |
6.021000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
9.606000E-01 |
| Tall-VS-Other |
6.666400E-01 |
| Tall-VS-Normal |
2.92299995319212E-09 |
| Follicular-VS-Other |
7.572800E-01 |
| Follicular-VS-Normal |
2.74813505285465E-12 |
| Other-VS-Normal |
2.360200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.12287956710588E-12 |
| N0-vs-N1 |
4.696800E-01 |
|
|
